90

Projects Completed

120

Targets & Drugs Modelled

140

Years of Combined Experience

200

Publications

How We Support Drug Development

 

Physiomics develops mathematical models to predict the effect of therapeutic drugs. With an experienced team of dedicated scientists we work with our clients to answer their R&D questions and de-risk drug development.

Pre-clinical

Translation

Clinical

Target engagement vs exposure

Drug mechanism of action

Mouse study design

Patient stratification

Dose and schedule selection for Ph1

Modelling support for IND / CTA

Prediction of therapeutic window

Modelling dose reduction / holiday

Regulatory PK/PD

What Our Partners Are Saying 

“We have worked with Physiomics to help provide answers to some critical early clinical development questions with CCS1477, our novel p300/CBP inhibitor. The analysis performed by Physiomics and the interpretation and input from their modelling experts has been invaluable. We now have the comfort that the next steps we are taking with the development of CCS1477 are data driven and validated through expert modelling data. Thanks for all your help.”

 

Nigel Brooks, Director Translational Science
Cellcentric
“Physiomics has provided PK/PD modelling and data analysis expertise on several of our oncology projects. We have found the group to be talented, experienced and committed to delivering high quality results in a timely manner. Physiomics has helped us achieve a more quantitative and translational understanding of our novel molecules.”

 

Phil Jeffrey, SVP Preclinical Development
Bicycle Therapeutics
“We have worked with Physiomics on a PK/PD modelling project for our molecule NM26-2198, intended for use in patients with inflammatory disease. The work has been highly productive, valuable and enjoyable. The Physiomics team are knowledgeable, helpful and dedicated to provide the expertise required to bring the project to fruition. Based on this excellent collaboration we will certainly be working with Physiomics again.”

 

Daniel Snell, VP Translational Science
Numab Therapeutics AG

Interested in speaking with a consultant?

We’ll arrange a brief consultation for you with a specialist in our team.

Learn More